1.Efficacy of ondansetron is cisplatin-induced nausea and vomiting.
Keum Jung KIM ; Jung Baik KIM ; Kwang Mi KIM ; Jung Sook PARK ; Soo Hee PARK ; Si Young KIM ; Hwi Joong YOON ; Kyung Sam CHO
Journal of the Korean Cancer Association 1993;25(6):975-981
No abstract available.
Nausea*
;
Ondansetron*
;
Vomiting*
2.Accidental Epidural Injection of Ondansetron : A case report.
Bo Song KIM ; Ho Sung KWAK ; Pil Jae LIM
Korean Journal of Anesthesiology 2007;52(6):712-714
We encountered a case of an accidental epidural injection of ondansetron through an epidural catheter. No neurological complications were noted. This case highlights the need for more attention to minimize the risk of epidural injections.
Catheters
;
Injections, Epidural*
;
Ondansetron*
3.Should ondansetron be used as a routine prophylaxis agent for postoperative nausea and vomiting?.
Mark C KENDALL ; Lucas J CASTRO-ALVES
Korean Journal of Anesthesiology 2018;71(5):413-414
No abstract available.
Ondansetron*
;
Postoperative Nausea and Vomiting*
4.Effect of ondansetron in prevention of nausea and vomiting associated with cisplatin chemothrapy in cancer patients.
Sang Won SHIN ; Kyung Mook CHOI ; Jong Eun YUN ; Sang Myun PARK ; Chul Won CHOI ; Joon Suk KIM
Journal of the Korean Cancer Association 1993;25(2):299-306
No abstract available.
Cisplatin*
;
Humans
;
Nausea*
;
Ondansetron*
;
Vomiting*
5.A comparison of the acute antiemetic effect of ondansetron with combination of metoclopramide, dexamethasone, lorazepam in patients receiving cisplatin.
Seung Ho BAICK ; Mi Kyung CHA ; Yong Wook CHO ; Do Yeun OH ; Sun Joo KIM
Journal of the Korean Cancer Association 1992;24(5):759-765
No abstract available.
Antiemetics*
;
Cisplatin*
;
Dexamethasone*
;
Humans
;
Lorazepam*
;
Metoclopramide*
;
Ondansetron*
6.A randomized comparison of antiemetic effect of ondansetron versus MDL(metoclopramide/dexamethasone/lorazepam) in patients receiving cisplatin-based combination chemotherapy.
Young Hyuck IM ; Young Suk PARK ; Joungsoon JANG ; Jae Yong LEE ; Sungsoo YOON ; Dae Seog HEO ; Yung Jue BANG ; Noe Kyeong KIM
Journal of the Korean Cancer Association 1992;24(3):378-389
No abstract available.
Antiemetics*
;
Drug Therapy, Combination*
;
Humans
;
Ondansetron*
7.Comparative study of an aprepitant regimen with an ondansetron regimen, for efficacy in gynecological cancer patients with chemotherapy.
Korean Journal of Obstetrics and Gynecology 2009;52(5):538-544
OBJECTIVE: We compared the impact of chemotherapy-induced nausea and vomiting (CINV) on patients of an aprepitant regimen with an ondansetron regimen, for antiemetic efficacy after highly emetogenic chemotherapy (HEC). METHODS: The study was performed prospective on 61 patients who is diagnosed initially the gynecological cancer during chemotherapy at Gospel hospital of Kosin university between March 2007 and October 2007. The study was divided according to an aprepitant/ondansetron regimen. The efficacy of controlling acute (during the 24 hours after chemotherapy) /delayed (day 2 days thought 5) nausea, vomiting and adverse effects were compared. Statistical analysis was performed using the chi-square test. RESULTS: The efficacy of controlling nausea with an aprepitant regimen and an ondansetron regimen was 86.7%, 83.9% in acute periods (Pvalue= 0.742) and 99%, 83.9% in delayed periods (P-value=0.083), respectively. The efficacy of controlling vomiting with an aprepitant regimen and an ondansetron regimen was 93.3%, 90.3% in acute periods (P-value=0.809) and 96.7%, 83.9% in delayed periods (Pvalue= 0.034), respectively. The efficacy of controlling delayed vomiting with an aprepitant regimen reported significantly. The common adverse effects in both groups were not significantly. CONCLUSION: The regimen including aprepitant was superior in preventing CINV as compared with a regimen in which both ondansetron and dexamethasone were given delayed periods in patients receiving chemotherapy
Dexamethasone
;
Humans
;
Morpholines
;
Nausea
;
Ondansetron
;
Prospective Studies
;
Vomiting
8.Comparative study of an aprepitant regimen with an ondansetron regimen, for efficacy in gynecological cancer patients with chemotherapy.
Korean Journal of Obstetrics and Gynecology 2009;52(5):538-544
OBJECTIVE: We compared the impact of chemotherapy-induced nausea and vomiting (CINV) on patients of an aprepitant regimen with an ondansetron regimen, for antiemetic efficacy after highly emetogenic chemotherapy (HEC). METHODS: The study was performed prospective on 61 patients who is diagnosed initially the gynecological cancer during chemotherapy at Gospel hospital of Kosin university between March 2007 and October 2007. The study was divided according to an aprepitant/ondansetron regimen. The efficacy of controlling acute (during the 24 hours after chemotherapy) /delayed (day 2 days thought 5) nausea, vomiting and adverse effects were compared. Statistical analysis was performed using the chi-square test. RESULTS: The efficacy of controlling nausea with an aprepitant regimen and an ondansetron regimen was 86.7%, 83.9% in acute periods (Pvalue= 0.742) and 99%, 83.9% in delayed periods (P-value=0.083), respectively. The efficacy of controlling vomiting with an aprepitant regimen and an ondansetron regimen was 93.3%, 90.3% in acute periods (P-value=0.809) and 96.7%, 83.9% in delayed periods (Pvalue= 0.034), respectively. The efficacy of controlling delayed vomiting with an aprepitant regimen reported significantly. The common adverse effects in both groups were not significantly. CONCLUSION: The regimen including aprepitant was superior in preventing CINV as compared with a regimen in which both ondansetron and dexamethasone were given delayed periods in patients receiving chemotherapy
Dexamethasone
;
Humans
;
Morpholines
;
Nausea
;
Ondansetron
;
Prospective Studies
;
Vomiting
9.A prospective randomized comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cisplatinum based combination chemotherapy.
Tejune CHUNG ; Seung Chul SHIM ; Kyung Won KANG ; Il Young CHOI
Journal of the Korean Cancer Association 1991;23(2):418-423
No abstract available.
Drug Therapy, Combination*
;
Metoclopramide*
;
Ondansetron*
;
Prospective Studies*
;
Vomiting*
10.Pain on Injection of Rocuronium: The Effect of Pretreatment of Lidocaine, Fentanyl, and Ondansetron.
Soo Kyung LEE ; Jung Mee LEE ; Young Mi KIM ; Hyun Soo MOON
Korean Journal of Anesthesiology 2004;46(2):151-154
BACKGROUND:Rocuronium is given for precurarization, timing or priming before the induction of anesthesia. The incidence of pain on injecting rocuronium is high and can be very distressing. The goal of this study was to evaluate whether pretreating lidocaine, fentanyl, or ondansetron i.v. can decrease the incidence and severity of injection pain. METHODS: One hundred and fifty patients were randomly allocated into five groups: patients in groups I, II, III, IV, and V received saline (3 ml), lidocaine 30 mg, lidocaine 50 mg, fentanyl 100microgram, or ondansetron 4 mg after manually occluding the forearm. The occlusion was released and rocuronium 0.6 mg/kg was injected. The patients were then observed and asked whether they had pain in the arm, and responses were assessed. RESULTS: The mean (median) pain scores in gorups I, II, III, IV, and V were 1.9 (2), 1.0 (1), 0.73 (1), 1.33 (1), and 1.2 (1), respectively. We found that 7%, 37%, 47%, 20%, and 20% of patients in groups I, II, III, IV and V reported no pain. Moderate to severe pain was seen in 60%, 33%, 20%, 40%, and 33% of patients in groups I, II, III, IV, and V, respectively. CONCLUSIONS: Lidocaine, fentanyl, and ondansetron reduced rocuronium injection pain. Of these drugs, lidocaine seems to be the most effective. Fentanyl and ondansetron proved less effective than lidocaine.
Anesthesia
;
Arm
;
Fentanyl*
;
Forearm
;
Humans
;
Incidence
;
Lidocaine*
;
Ondansetron*